PSNL News & Events

Personalis announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. "Personalis is no longer just participating in the MRD market; we are defining its future," said Chris Hall, Chief Executive Officer of Personalis. "Rich has been the principal architect of our most significant product and technology leaps, including NeXT Personal, and designed the clinical evidence strategy that has accelerated adoption of our ultrasensitive MRD tests. By elevating him to President, we are aligning our visionary R&D with the need to integrate the technology into pharmaceutical drug trials and physician workflows to help patients fight cancer."

Personalis announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article showed that ultrasensitive molecular residual disease - MRD - testing with NeXT Personal can perform better than current standard approaches in predicting patient outcomes following neoadjuvant therapy, or NAT. The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer. The results demonstrate the ability of NeXT Personal to provide a more precise risk-stratification for patients who have received NAT. A key finding of the study was the necessity of the ultrasensitive range for accurately tracking patient response to neoadjuvant therapy. Detectable ctDNA post-NAT was associated with a 4 to 9 times higher likelihood of relapse. Patients with detectable ctDNA up to 12 months post-surgery were more than 100 times more likely to experience disease recurrence. The findings reinforce the NeXT Personal test's ability to detect ctDNA at ultrasensitive levels, providing a window for earlier clinical intervention that other approaches may miss.

Reports Q4 revenue $17.3M, consensus $17.1M. "Our performance in 2025 was transformative, demonstrated by 400% year-over-year clinical volume growth and pivotal Medicare coverage for breast and lung cancer," said Chris Hall, Chief Executive Officer and President. "We enter 2026 with a fortified balance sheet of approximately $240 million in cash, which allows us to expand our investments in our 'Win-in-MRD' strategy. While we are in the early stages of reimbursement, we are driving volume now to secure long-term market leadership. We expect 2026 to be a year of rapid commercial expansion, with clinical revenue projected to grow approximately five-fold as we operationalize our recent coverage wins."